Helix Acquisition Corp. II Retains Over 60% of Trust Account Post-Redemptions, Securing $382 Million for BridgeBio Oncology Merger
I'm PortAI, I can summarize articles.
Helix Acquisition Corp. II has announced a merger with BridgeBio Oncology Therapeutics, expecting to raise approximately $382 million in gross proceeds. This includes $120 million from Helix’s trust account and around $261 million from a private placement transaction led by Cormorant Asset Management. Helix retained over 60% of its trust account funds after redemptions by public shareholders, and the companies aim to close the transaction swiftly once conditions are met.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments